Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion

Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Ophthalmology, American Uni...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paulose R, Chhablani J, Dedhia CJ, Stewart MW, Mansour AM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	ziv-aflibercept retinal vein occlusion cystoid macular edema Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d46c2e2c7cbf4185b6133259e5049e92
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d46c2e2c7cbf4185b6133259e5049e92
record_format	dspace
spelling	oai:doaj.org-article:d46c2e2c7cbf4185b6133259e5049e922021-12-02T03:50:35ZIntravitreal ziv-aflibercept for macular edema following retinal vein occlusion1177-5483https://doaj.org/article/d46c2e2c7cbf4185b6133259e5049e922016-09-01T00:00:00Zhttps://www.dovepress.com/intravitreal-ziv-aflibercept-for-macular-edema-following-retinal-vein--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Ophthalmology, American University of Beirut, 4Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon Aim: To report the efficacy of intravitreal ziv-aflibercept injections in eyes with macular edema due to retinal vein occlusions (RVOs). Methods: Consecutive patients with persistent or recurrent macular edema (central macula thickness >250 µm) due to RVO were enrolled in this prospective study. Study eyes received intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) at baseline. Patients were reassessed monthly for 4 months and given additional injections pro re nata for worsening best-corrected visual acuity (BCVA), intraretinal edema or subretinal fluid seen on spectral domain optical coherence tomography, or central macular thickness (CMT) measurements >250 µm. The primary endpoint was improvement in mean CMT at 4 months. Secondary endpoints included improvement in mean BCVA, and ocular and systemic safety signals. Results: Nine eyes (five central and four branch RVOs) of nine patients were enrolled. The mean ± standard deviation CMT decreased from 604±199 µm at baseline to 319±115 µm (P=0.001) at 1 month and to 351±205 µm (P=0.026) at 4 months. The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits. No safety signals were noted. Conclusion: In this small prospective study, intravitreal ziv-aflibercept significantly improved mean CMT in eyes with persistent or recurrent macular edema due to RVOs. Prospective, randomized trials comparing ziv-aflibercept with standard pharmacotherapy are needed to better define efficacy and safety. Keywords: ziv-aflibercept, retinal vein occlusion, cystoid macular edemaPaulose RChhablani JDedhia CJStewart MWMansour AMDove Medical Pressarticleziv-afliberceptretinal vein occlusioncystoid macular edemaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 1853-1858 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	ziv-aflibercept retinal vein occlusion cystoid macular edema Ophthalmology RE1-994
spellingShingle	ziv-aflibercept retinal vein occlusion cystoid macular edema Ophthalmology RE1-994 Paulose R Chhablani J Dedhia CJ Stewart MW Mansour AM Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
description	Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Ophthalmology, American University of Beirut, 4Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon Aim: To report the efficacy of intravitreal ziv-aflibercept injections in eyes with macular edema due to retinal vein occlusions (RVOs). Methods: Consecutive patients with persistent or recurrent macular edema (central macula thickness >250 µm) due to RVO were enrolled in this prospective study. Study eyes received intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) at baseline. Patients were reassessed monthly for 4 months and given additional injections pro re nata for worsening best-corrected visual acuity (BCVA), intraretinal edema or subretinal fluid seen on spectral domain optical coherence tomography, or central macular thickness (CMT) measurements >250 µm. The primary endpoint was improvement in mean CMT at 4 months. Secondary endpoints included improvement in mean BCVA, and ocular and systemic safety signals. Results: Nine eyes (five central and four branch RVOs) of nine patients were enrolled. The mean ± standard deviation CMT decreased from 604±199 µm at baseline to 319±115 µm (P=0.001) at 1 month and to 351±205 µm (P=0.026) at 4 months. The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits. No safety signals were noted. Conclusion: In this small prospective study, intravitreal ziv-aflibercept significantly improved mean CMT in eyes with persistent or recurrent macular edema due to RVOs. Prospective, randomized trials comparing ziv-aflibercept with standard pharmacotherapy are needed to better define efficacy and safety. Keywords: ziv-aflibercept, retinal vein occlusion, cystoid macular edema
format	article
author	Paulose R Chhablani J Dedhia CJ Stewart MW Mansour AM
author_facet	Paulose R Chhablani J Dedhia CJ Stewart MW Mansour AM
author_sort	Paulose R
title	Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
title_short	Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
title_full	Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
title_fullStr	Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
title_full_unstemmed	Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
title_sort	intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/d46c2e2c7cbf4185b6133259e5049e92
work_keys_str_mv	AT pauloser intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion AT chhablanij intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion AT dedhiacj intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion AT stewartmw intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion AT mansouram intravitrealzivafliberceptformacularedemafollowingretinalveinocclusion
_version_	1718401616297590784

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion

Ejemplares similares